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Background: Post-transplantation encapsulating peritoneal sclerosis (EPS) causing bowel obstruction has been
identified as a serious complication after kidney transplantation in patients previously treated with peritoneal dialysis.
Systemic inflammation and abnormalities on an abdominal computed tomography (CT) scan are important hallmarks
of EPS. To our knowledge, this is the first report of a case being diagnosed with late-onset post-transplantation EPS
without systemic inflammation or abnormalities on a CT scan which could only be diagnosed by laparotomy.
Case presentation: A 59-year old female presented because of symptoms of bowel obstruction 33 months after
kidney transplantation. The patient had a 26-month history of peritoneal dialysis before her first kidney transplantation
and was treated with peritoneal dialysis for 4 years before undergoing a second kidney transplantation. Physical
examination was unremarkable and laboratory tests showed no signs of systemic inflammation (C-reactive
protein <1 mg/L). An abdominal CT scan did not reveal any abnormalities fitting the diagnosis of EPS, except a
“feces sign”. Given the severity of the progressive symptoms, a diagnostic laparotomy was performed, visualizing a
classical EPS. Total peritonectomy and enterolysis were performed, leading to restoration of peristalsis.
Conclusion: EPS may occur several years after kidney transplantation in the absence of inflammation and typical
radiological abnormalities. Obtaining a diagnosis of post-transplantation EPS is challenging, however, a low threshold
for surgical exploration in case of high clinical suspicion and negative findings on the CT scan is mandatory.
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Encapsulating peritoneal (EPS) sclerosis is a rare but
potentially lethal complication of peritoneal dialysis
(PD) treatment, characterized by excessive sclerotic and
fibrotic thickening of the peritoneal membrane, which
may eventually lead to bowel obstruction [1,2]. In recent
years, EPS occurring after kidney transplantation (KTX)
in patients who were previously being treated with PD
(coined post-transplantation EPS) is increasingly observed
[3,4]. The prevalence of post-transplantation EPS is
reported to be 1-3% in PD patients undergoing KTX
and is associated with significant mortality [4-6]. The* Correspondence: m.g.h.betjes@erasmusmc.nl
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reproduction in any medium, provided the orprognosis of EPS can be substantially improved by
treating with tamoxifen, anti-inflammatory drugs, and
timely surgical intervention [7,8].
The time from KTX until development of post-trans-
plantation EPS is typically short with the vast majority
occurring within the first year after transplantation [4,9,10].
In most cases, EPS is accompanied by systemic inflamma-
tion [11]. The presence of symptoms of obstructed bowel
movements and characteristic findings on computed tom-
ography (CT) scan of the abdomen are mandatory for the
clinical diagnosis of EPS [1,12]. We here report a unique
case of post-transplantation EPS presenting 33 months
after KTX in a patient with progressive symptoms of
intestinal obstruction without systemic inflammation
and absence of typical radiological abnormalities. This
unusual presentation emphasizes the value of consideringtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Abdominal computed tomography scan
demonstrating the presence of feculent material in the small
bowel (arrow) and a small amount of localized ascites.
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there is a high degree of suspicion for this condition in
former PD patients undergoing KTX, a laparotomy by a
surgeon with EPS experience is recommended.
Case presentation
A 59-year old female was referred to our EPS center out-
patient clinic because of progressive symptoms of bowel
obstruction almost 33 months after KTX. The nausea,
vomiting and abdominal pain predominantly occurred
shortly after eating solid meals. The patient’s medical
history included end stage renal disease secondary to
polycystic kidney disease. She had a 26-month history
of PD before her first KTX and was treated with PD for
almost 4 years before undergoing her second trans-
plantation with a kidney from a living donor. During
PD treatment she had no signs of ultrafiltration failure and
had experienced one uncomplicated peritonitis episode
with Staphylococcus aureus.
Her symptoms had started insidiously one year after
transplantation while she received a tacrolimus-based
immunosuppressive regimen. Diagnostic work-up did not
show any signs of inflammation with normal radiological
imaging of the abdomen. Almost 23 months after her last
transplantation a diagnostic laparoscopy was performed
elsewhere, but no macroscopic abnormalities were reported.
However, peritoneal biopsies were taken and showed signs
of fibrosis without active or chronic infiltration. As the
symptoms and weight loss persisted, she was referred to
our clinic for a second opinion.
At presentation she had lost 5 kilograms of weight over
the last year (BMI 19 kg/m2) and was unable to tolerate
solid foods. No abnormalities were found at physical
examination, and laboratory tests showed no signs of
systemic inflammation (C-reactive protein (CRP) < 1 mg/L,
albumin 40 g/L) and adequate graft function (serum
creatinine 91 umol/L). A recent abdominal CT scan did
not reveal any abnormalities compatible with the diagnosis
of EPS although a “feces sign”, consisting of intraluminal
feculent material in the small bowel, was observed
(Figure 1). Additionally, the CT scan showed a small
amount of localized ascites in the abdomen but no other
diagnostic signs of EPS like bowel tethering, calcifications,
or peritoneal thickening. Despite the absence of typical
findings, but the severity of the progressive symptoms we
considered the possibility of localized EPS, a condition in
which the peritoneum shows encapsulating sclerosis
predominantly at the level of the terminal ileum [13,14].
Surgical exploration was considered as a final diagnostic
procedure. During the operation, a classical picture of EPS
was found characterized by a thin cocoon-like sclerotic
membrane encasing the small bowel (Figure 2A). A
complete resection of the encapsulating sclerotic mem-
brane and total enterolysis were performed, combinedwith complete removal of the thickened visceral peritoneal
membrane (Figure 2B), which lead to restoration of peri-
stalsis durante operationem. Histologic evaluation of the
visceral peritoneal membrane was performed, supporting
the diagnosis of EPS, and showed dense sclerosis with
patchy mononuclear cell infiltration (Figure 3). On the
fifth postoperative day, an emergency ileocecal resection
with protective loop ileostomy was necessary because of
a perforation at the level of the ileocecal junction where a
serosal injury had been made during the first operation.
The patient recovered soon after surgery, and in an attempt
to prevent further recurrences, was prescribed 10 mg
twice-daily tamoxifen and 10 mg once daily prednisolone.
After five weeks the loop ileostomy was closed and bowel
continuity restored, with an uneventful postoperative course.
One year after EPS surgery, the patient has gained almost
20 kilograms in body weight and is doing well with a
stable graft function and without clinical signs of EPS
recurrence.
Discussion
We report a case of late-onset EPS in a patient presenting
33 months after KTX, with the diagnosis being suspected
only on basis of her history of PD and progressive symp-
toms of intestinal obstruction.
The risk of developing EPS primarily depends on the
duration of PD, however, EPS occurs more frequently in
patients discontinuing PD treatment [9,15]. In this respect,
post-transplantation EPS has gained attention in recent
years. The timeline from KTX until diagnosis of EPS varies
widely from just a few months to over 2 years. However,
most cases of post-transplantation EPS develop within the
relatively short time period of one year after transplantation
[4,5,9,10].
The current leading theory of EPS pathophysiology
assumes that a second hit on an inflamed peritoneal
Figure 2 Macroscopic appearance of EPS before and after surgery. During the laparotomy, a classical picture of EPS was observed
characterized by a thin cocoon-like sclerotic membrane encasing the small bowel (A). A complete resection of the encapsulating sclerotic
membrane and total enterolysis were performed, combined with removal of the thickened visceral peritoneal membrane (B).
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of EPS [2]. In line with this theory, cessation of PD treat-
ment causing accumulation of inflammatory and fibrotic
mediators [16] may serve as a “second hit” in the develop-
ment of post-transplantation EPS. In addition, the time
from KTX until final EPS diagnosis in our patient was rela-
tively long while patient received tacrolimus monotherapy,
and therefore in support of the concept that transplantation
per se or exposure to a profibrotic calcineurin inhibitor
may have played a role in the development of EPS.
Reaching a definite diagnosis of post-transplantation
EPS can be difficult, as is illustrated by our patient, due
to aspecific symptoms of bowel obstruction and absence
of typical radiological findings. Classically, EPS has an
initial inflammatory phase with elevated markers of
inflammation, such as CRP [2,11,17]. In this case the
patient presented with a non-elevated CRP level. This
finding may be explained by the fact that EPS in thisFigure 3 Microscopic evaluation of the visceral peritoneal membrane re
Immunostaining with anti-CD3 antibody (A,C) and anti-CD68 antibody (B,D).patient was detected in its final stage in which the
process of inflammation subsided and only a cocoon-like
thickened peritoneal membrane remained.
The CT scan aids in the diagnosis of EPS, and according
to Tarzi and colleagues may reveal characteristic findings
such as peritoneal calcifications, peritoneal thickening,
bowel tethering and ascites [12]. In our patient, only a
“feces sign [18]” was detected, which may indicate a
stenosis in the small bowel, but no classic signs of EPS
were found. The thin nature of the sclerotic membrane
that covered the bowels apparently prevented detection by
CT scan and could only be detected during surgical ex-
ploration. The final diagnosis in our patient was made
during an exploratory laparotomy, indicating that a
low threshold for surgical exploration is needed in case
of high clinical suspicion and negative findings on the
CT scan. Additionally, surgical exploration can offer a
therapeutic benefit as soon as EPS is confirmed, asvealed dense sclerosis with patchy mononuclear cell infiltration.
Original magnification × 200. Scale bar represents 400 μm.
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the same operation.
Although steroids and tamoxifen have shown to be of
benefit in the treatment of EPS, this may only be the
case in the early stage of active disease that is characterized
by elevated markers of inflammation [11]. The ultimate
treatment of EPS is surgery, involving resection of the
sclerotic membrane. Our patient developed a peritonitis
on the fifth day after surgery due to a perforation at the
ileocecal junction, based on a single serosal injury that
was made during the initial operation, and which was
sutured straight away. This underscores the hazards of
EPS surgery, which is a challenging and time consuming
procedure, and preferably should be performed in a spe-
cialized center [19]. In experienced hands, elective EPS
surgery has a mortality rate <10% [20], however, this may
be much higher in patients with an acute indication.
Recurrence rates after surgery are high and reported to be
25% in some studies [21]. Our patient received tamoxifen
and prednisolone until one year after surgery. Although the
benefits of tamoxifen have not been clearly determined, it
is believed to have antifibrotic properties [1] and therefore
may be useful in preventing recurrences.
Conclusion
In conclusion, EPS may occur several years after trans-
plantation in the absence of systemic inflammation and
typical radiological abnormalities. Obtaining an accurate
diagnosis of post-transplantation EPS is challenging,
however, a low threshold for surgical exploration in
case of high clinical suspicion and without positive findings
on the CT scan is mandatory. Surgical treatment for EPS
by an experienced surgeon may be indicated to restore
bowel movement, improve nutritional status, and alleviate
symptoms. Furthermore, surgical exploration in a special-
ized center should be considered earlier rather than later
when EPS is suspected. Finally, this case underscores the
important value of considering a possible diagnosis of
late-onset EPS even several years after KTX in patients
with a long duration of pre-transplant PD.
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